| 摘要: |
| 新型冠状病毒肺炎的发生,给我国各行业都造成了巨大的影响,也对临床试验的顺利开展也带来了很多的困难。目前来看,长期抗疫已经不可避免,疫情期间开展临床试验已经成为常态。临床试验中,应该将保护受试者的安全放在首位。本文介绍中国医学科学院皮肤病医院I期临床在2020年5月至2020年12月开展的5个临床试验项目,通过试验前期、筛选期、试验期、清洗期、随访期采取的一系列措施,来保障受试者的安全,确保临床试验顺利的进行,试验数据和结果的可靠性、完整性。 |
| 关键词: 新型冠状病毒肺炎 Ⅰ期临床试验 受试者保护 |
| DOI:10.13506/j.cnki.jpr.2022.02.008 |
| 基金项目: |
|
Publication Date:February 25, 2022
|
|
| Protection of subjects in phase I clinical trials during normalized anti-epidemic period |
| CAI Baole,MA Pengcheng |
| (Hospital for Skin Diseases,Chinese Academy of Medical Science,Nanjing 210002,China) |
| Abstract: |
| The occurrence of COVID-19 has great impact on various industries in China. It also brings a lot of difficulties to the smooth development of clinical trials. At present, long-term anti epidemic is inevitable, and clinical trials during the epidemic have become the norm. In clinical trials, the safety of subjects should be put in the first place.This paper introduces the five clinical trials carried out in the Hospital of Dermatology,Chinese Academy of Medical Sciences and Peking Union Medical College from May 2020 to December 2020,Through a series of measures taken in the early stage, screening period, test period, cleaning period and follow-up period, the safety of subjects is guaranteed, and the reliability and integrity of test data and results are ensured. |
| Key words: COVID-19 Phase I clinical trial Subject protection |